The role of ACKR3 in breast, lung and brain cancer. - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Molecular Pharmacology Année : 2019

The role of ACKR3 in breast, lung and brain cancer.


Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.
Fichier principal
Vignette du fichier
Neves-Mol-Pharma.pdf (486.8 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-02364296 , version 1 (29-11-2020)



Maria Neves, Amos Fumagalli, Jelle van den Bor, Philippe Marin, Martine Smit, et al.. The role of ACKR3 in breast, lung and brain cancer.. Molecular Pharmacology, 2019, 96, pp.mol.118.115279. ⟨10.1124/mol.118.115279⟩. ⟨hal-02364296⟩
50 Consultations
54 Téléchargements



Gmail Facebook X LinkedIn More